Publications in VIVO

Co-Author Network

Co-Investigator Network

Bannister, Thomas Faculty Member

Positions

Associate Scientific Director II, Translational Research Institute, The Scripps Research Institute 2005 -
Assistant Professor of Chemistry (Joint Appointment), Chemistry, The Scripps Research Institute

Dr. Thomas Bannister uses all modern synthesis techniques to help our interdisciplinary Drug Discovery team rapidly design potential drug candidates for treating multiple sclerosis, diabetes, and addiction.

Publications

selected publications

academic article
- Chowdhury, S., Chen, Y. T., Fang, X. G., Grant, W., Pocas, J., Cameron, M. D., Ruiz, C., Lin, L., Park, H., Schroter, T., Bannister, T. D., LoGrasso, P. V., et al. Amino acid derived quinazolines as Rock/PKA inhibitors Bioorganic & Medicinal Chemistry Letters 2013 23:1592-1599 DOI:10.1016/j.bmcl.2013.01.109 PMID:23416002
- Amundsen, S. K., Spicer, T., Karabulut, A. C., Londono, L. M., Eberhart, C., Vega, V. F., Bannister, T. D., Hodder, P., Smith, G. R. Small-molecule inhibitors of bacterial addab and recbcd helicase-nuclease DNA repair enzymes ACS Chemical Biology 2012 7:879-891 DOI:10.1021/cb300018x PMID:22443934
- Chen, Y. T., Vojkovsky, T., Fang, X. G., Pocas, J. R., Grant, W., Handy, A. M. W., Schroter, T., LoGrasso, P., Bannister, T. D., Fang, Y. B. Asymmetric synthesis of potent chroman-based rho kinase (rock-ii) inhibitors MedChemComm 2011 2:73-75 DOI:10.1039/c0md00194e
- Sessions, E. H., Chowdhury, S., Yin, Y., Pocas, J. R., Grant, W., Schroter, T., Lin, L., Ruiz, C., Cameron, M. D., LoGrasso, P., Bannister, T. D., Feng, Y. B. Discovery and optimization of indole and 7-azaindoles as rho kinase (rock) inhibitors (part-ii) Bioorganic & Medicinal Chemistry Letters 2011 21:7113-7118 DOI:10.1016/j.bmcl.2011.09.084
- Chowdhury, S., Sessions, E. H., Pocas, J. R., Grant, W., Schroter, T., Lin, L., Ruiz, C., Cameron, M. D., Schurer, S., LoGrasso, P., Bannister, T. D., Feng, Y. B. Discovery and optimization of indoles and 7-azaindoles as rho kinase (rock) inhibitors (part-i) Bioorganic & Medicinal Chemistry Letters 2011 21:7107-7112 DOI:10.1016/j.bmcl.2011.09.083
- Bialkowska, A. B., Crisp, M., Bannister, T., He, Y. J., Chowdhury, S., Schurer, S., Chase, P., Spicer, T., Madoux, F., Tian, C. L., Hodder, P., Zaharevitz, D., et al. Identification of small-molecule inhibitors of the colorectal cancer oncogene kruppel-like factor 5 expression by ultrahigh-throughput screening Molecular Cancer Therapeutics 2011 10:2043-2051 DOI:10.1158/1535-7163.mct-11-0550
- Fang, X. A., Chen, Y. T., Sessions, E. H., Chowdhury, S., Vojkovsky, T., Yin, Y., Pocas, J. R., Grant, W., Schroter, T., Lin, L., Ruiz, C., Cameron, M. D., et al. Synthesis and biological evaluation of 4-quinazolinones as rho kinase inhibitors Bioorganic & Medicinal Chemistry Letters 2011 21:1844-1848 DOI:10.1016/j.bmcl.2011.01.039
- Sessions, E. H., Smolinski, M., Wang, B., Frackowiak, B., Chowdhury, S., Yin, Y., Chen, Y. T., Ruiz, C., Lin, L., Pocas, J., Schroter, T., Cameron, M. D., et al. The development of benzimidazoles as selective rho kinase inhibitors Bioorganic & Medicinal Chemistry Letters 2010 20:1939-1943 DOI:10.1016/j.bmcl.2010.01.124
- Sessions, E. H., Yin, Y., Bannister, T. D., Weiser, A., Griffin, E., Pocas, J., Cameron, M. D., Ruiz, C., Lin, L., Schurer, S. C., Schroter, T., LoGrasso, P., et al. Benzimidazole- and benzoxazole-based inhibitors of rho kinase Bioorganic & Medicinal Chemistry Letters 2008 18:6390-6393 DOI:10.1016/j.bmcl.2008.10.095
- Chen, Y. T., Bannister, T. D., Weiser, A., Griffin, E., Lin, L., Ruiz, C., Cameron, M. D., Schurer, S., Duckett, D., Schroter, T., LoGrasso, P., Feng, Y. B. Chroman-3-amides as potent rho kinase inhibitors Bioorganic & Medicinal Chemistry Letters 2008 18:6406-6409 DOI:10.1016/j.bmcl.2008.10.080
- Lin, J., Deng, H. F., Jin, L., Pandey, P., Quinn, J., Cantin, S., Rynkiewicz, M. J., Gorga, J. C., Bibbins, F., Celatka, C. A., Nagafuji, P., Bannister, T. D., et al. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor xia as novel anticoagulants Journal of Medicinal Chemistry 2006 49:7781-7791 DOI:10.1021/jm060978s
- Deng, H. F., Bannister, T. D., Jin, L., Babine, R. E., Quinn, J., Nagafuji, P., Celatka, C. A., Lin, J., Lazarova, T. I., Rynkiewicz, M. J., Bibbins, F., Pandey, P., et al. Synthesis, sar exploration, and x-ray crystal structures of factor xia inhibitors containing an alpha-ketothiazole arginine Bioorganic & Medicinal Chemistry Letters 2006 16:3049-3054 DOI:10.1016/j.bmcl.2006.02.052
- Roush, W. R., Bannister, T. D., Wendt, M. D., VanNieuwenhze, M. S., Gustin, D. J., Dilley, G. J., Lane, G. C., Scheidt, K. A., Smith, W. J. An nmr method for assigning relative stereochemistry to beta-hydroxy ketones deriving from aldol reactions of methyl ketones Journal of Organic Chemistry 2002 67:4284-4289 DOI:10.1021/jo0164148
- Roush, W. R., Bannister, T. D., Wendt, M. D., Jablonowski, J. A., Scheidt, K. A. Studies on the synthesis of bafilomycin a(1): Stereochemical aspects of the fragment assembly aldol reaction for construction of the c(13)-c(25) segment Journal of Organic Chemistry 2002 67:4275-4283 DOI:10.1021/jo016413f
- Scheidt, K. A., Bannister, T. D., Tasaka, A., Wendt, M. D., Savall, B. M., Fegley, G. J., Roush, W. R. Total synthesis of (-)-bafilomycin a(1) Journal of the American Chemical Society 2002 124:6981-6990 DOI:10.1021/ja017885e
- Scheidt, K. A., Tasaka, A., Bannister, T. D., Wendt, M. D., Roush, W. R. Total synthesis of (-)-bafilomycin a(1): Application of diastereoselective crotylboration and methyl ketone aldol reactions Angewandte Chemie - International Edition 1999 38:1652-1655 DOI:10.1002/(sici)1521-3773(19990601)38:11<1652::aid-anie1652>3.0.co;2-k
- Roush, W. R., Bannister, T. D., Wendt, M. D. Concerning the diastereofacial selectivity of aldol reactions of chiral methyl ketone enolates - evidence for remote chelation in the bafilomycin aldol reaction Tetrahedron Letters 1993 34:8387-8390 DOI:10.1016/s0040-4039(00)61340-0
- Roush, W. R., Bannister, T. D. Stereoselective synthesis of the c(13)-c(25) segment of bafilomycin-a(1) Tetrahedron Letters 1992 33:3587-3590 DOI:10.1016/s0040-4039(00)92509-7

featured in

Research

research overview

Organic/Medicinal Chemistry and Drug Discovery

In our labs we strive to rapidly identify and optimize the potency and properties of lead compounds that we hope will be used to treat important human diseases. We work closely with molecular biologists, biochemists, computational chemists, and pharmacologists to pursue safe, effective, and patentable drug candidates. These compounds act at well-validated biological targets including kinases and G-protein coupled receptors. We use all modern synthesis techniques available to efficiently prepare the test molecules, with chemistry capable of generating a wide diversity of structures. We first prepare compounds in small amounts (<100mg) and then upon identification of a promising candidate for detailed testing of efficacy and safety we make larger amounts (0.5-5g). Projects that are ongoing or soon to be launched include the discovery of therapeutics for the treatment of multiple sclerosis, diabetes, drug and alcohol addiction, and hypertension.

principal investigator on

Discovery of potent and selective neuropeptide y y2 receptor antagonist probes awarded by National Institute on Alcohol Abuse and Alcoholism 2010 - 2014
Small molecule nociceptin receptor agonists to treat cocaine abuse awarded by National Institute on Drug Abuse 2012 - 2017

co-principal investigator on

Synthesis and evaluation of functionally biased opioid analgesics awarded by National Institute on Drug Abuse 2012 - 2017

Background

education and training

Ph.D. in Organic Chemistry, Indiana University 1991
M.Phil. Master of Philosophy, Yale University 1987
A.B. in Chemistry, Wabash College 1984